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Published by Bioscientifica Ltd.Correspondence
should be addressed
to B P Cummings
Email
bpc68@cornell.eduAbstractThere is a need to identify strategies for type 2 diabetes prevention. Therefore, we
investigated the efficacy of pioglitazone and alogliptin alone and in combination to
prevent type 2 diabetes onset in UCD-T2DM rats, a model of polygenic obese type 2 diabetes.
At 2months of age, ratswere divided into four groups: control, alogliptin (20 mg/kg per day),
pioglitazone (2.5 mg/kg per day), and alogliptinCpioglitazone. Non-fasting blood glucose
was measured weekly to determine diabetes onset. Pioglitazone alone and in combination
with alogliptin lead to a 5-month delay in diabetes onset despite promoting increased food
intake and body weight (BW). Alogliptin alone did not delay diabetes onset or affect food
intake or BW relative to controls. Fasting plasma glucose, insulin, and lipid concentrations
were lower and adiponectin concentrations were threefold higher in groups treated with
pioglitazone. All treatment groups demonstrated improvements in glucose tolerance
and insulin secretion during an oral glucose tolerance test with an additive improvement
observed with alogliptinCpioglitazone. Islet histology revealed an improvement of islet
morphology in all treatment groups compared with control. Pioglitazone treatment also
resulted in increased expression of markers of mitochondrial biogenesis in brown adipose
tissue and white adipose tissue, with mild elevations observed in animals treated with
alogliptin alone. Pioglitazonemarkedly delays the onset of type 2 diabetes in UCD-T2DM rats
through improvements of glucose tolerance, insulin sensitivity, islet function, and markers
of adipose mitochondrial biogenesis; however, addition of alogliptin at a dose of 20 mg/kg
per day to pioglitazone treatment does not enhance the prevention/delay of diabetes onset.Key Words
" pioglitazone
" type 2 diabetes
" alogliptin
" isletJournal of Endocrinology
(2014) 221, 133–144IntroductionThe prevalence of type 2 diabetes is steadily rising with
approximately one in ten adults affected in industrialized
countries (Danaei et al. 2011), necessitating the advent of
more effective therapeutic strategies for the preventionand treatment of type 2 diabetes (DeFronzo & Abdul-
Ghani 2011). While the pharmacotherapeutic options
for the treatment of type 2 diabetes are expanding and
improving, patients suffering from type 2 diabetes
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221 :1 134continue to experience a higher risk of developing co-
morbidities such as cardiovascular disease, cancer, and
renal failure (Ritz et al. 1999, Czyzyk & Szczepanik 2000,
Mazzone et al. 2008). Delaying the onset of frank type 2
diabetes will likely delay the development of these long-
term complications. The development of multimodal
therapies may be more effective in the treatment and
prevention of type 2 diabetes and its co-morbidities than
monotherapy. Two common drug targets for the treat-
ment of type 2 diabetes are peroxisome proliferator
receptor g (PPARg) and glucagon-like peptide 1 (GLP1).
PPARg is a nuclear receptor that is highly expressed
in adipose tissue and macrophages and acts to upregulate
the expression of factors involved in adipocyte differen-
tiation and triglyceride storage (Ferre 2004). PPARg is
targeted by the thiazolidinedione (TZD) class of drugs
(Nolte et al. 1998, Rosen & Spiegelman 2001, Semple et al.
2006). Agonism of PPARg by TZDs leads to decreases in
circulating glucose and lipid concentrations and marked
improvements of insulin sensitivity in type 2 diabetic
patients, making TZDs commonly prescribed for the
treatment of type 2 diabetes (Olefsky 2000, Sharma &
Staels 2007, Nissen et al. 2008). Pioglitazone is a member of
the TZD family and is commonly used in the treatment of
type 2 diabetes due to its potent glucose-lowering and
insulin-sensitizing effects (Olefsky 2000, Semple et al.
2006). Furthermore, a recent clinical study demonstrated
that pioglitazone treatment of patients with impaired
glucose tolerance reduced the risk of conversion to type 2
diabetes by 72%, demonstrating that pioglitazone alone
is an effective strategy for delaying type 2 diabetes onset
(DeFronzo et al. 2011).
GLP1 has become a well-established drug target for the
treatment of type 2 diabetes (Drucker & Nauck 2006). We
have previously reported that the GLP1 receptor agonist,
liraglutide, substantially delays the onset of diabetes in the
UCD-T2DM rat model (Cummings et al. 2010). Endogen-
ous GLP1 has a short half-life in the circulation of!2 min
due to rapid degradation by DPP-IV (Baggio & Drucker
2007). Therefore, DPP-IV inhibitors, such as aloglipitin,
have been developed in order to prolong the activity of
endogenous GLP1 (Feng et al. 2007, Thomas et al. 2008).
As an incretin hormone, GLP1 potentiates glucose-
stimulated insulin secretion (Baggio & Drucker 2007).
Furthermore, GLP1 has been shown to lower glucagon
secretion, preserve b-cell mass, and improve insulin
sensitivity, independent of its effects on insulin secretion
(Brubaker & Drucker 2004, Baggio & Drucker 2007).
Alogliptin has proven effective for improving glucose
and lipid homeostasis in rodent models of type 2 diabeteshttp://joe.endocrinology-journals.org  2014 Society for Endocrinology
DOI: 10.1530/JOE-13-0601 Printed in Great Britainand in type 2 diabetic patients (DeFronzo et al. 2008,
Moritoh et al. 2008, Pratley et al. 2009a, Zhang et al. 2011).
These complementary mechanisms of action suggest
that alogliptin and pioglitazone given in combination may
act synergistically to improve glucose and lipid homeo-
stasis. Indeed, studies on rodents and clinical studies on
type 2 diabetic patients report that addition of alogliptin to
pioglitazone monotherapy results in additive effects to
lower blood glucose concentrations (Moritoh et al. 2009,
Pratley et al. 2009b, Rosenstock et al. 2010, DeFronzo et al.
2012). However, the efficacy of alogliptin alone and in
combination with pioglitazone to delay the onset of type 2
diabetes has not been previously investigated. Therefore,
we used the UCD-T2DM rat model to test the hypothesis
that pioglitazone and alogliptin in combination would be
more effective in delaying type 2 diabetes onset in
prediabetic UCD-T2DM rats than either treatment alone.
The UCD-T2DM rat model develops adult-onset polygenic
obesity, insulin resistance, and subsequent type 2 diabetes
(Cummings et al. 2008).Materials and methods
Diets and animals
Male UCD-T2DM rats were individually housed in wire
cages in the Department of Nutrition animal facility at the
University of California, Davis, and maintained on a 14 h
light:10 h darkness cycle. Starting at 2 months of age, male
siblings were divided into four groups: control, alogliptin
(20 mg/kg per day), pioglitazone (2.5 mg/kg per day), and
alogliptinCpioglitazone (nZ32 per group). Groups were
matched for weight at the initiation of treatment and all
animals received ground chow (no. 5012, Ralston Purina,
Belmont, CA, USA). Drug compounds were mixed into the
ground chow such that animals received the appropriate
daily dose throughout the study. Food intake and
body weight (BW) were measured three times a week.
Non-fasting blood glucose was monitored every week with a
glucose meter (One-Touch Ultra, LifeScan, Milpitas, CA,
USA) at 1300–1400 h using a lancet to collect a drop of blood
from the tail. Diabetes onset was defined as a non-fasted
blood glucose value above 11.1 mmol/l on 2 consecutive
weeks (Cummings et al. 2008). One half of the animals in
each group (nZ16) were killed for tissue collection at
6.5 months of age (short-term study), and the remaining
half (nZ16) continued treatment up to 1 year of age (long-
term study). Monthly blood samples were collected up to
8 months of age. An oral glucose tolerance test (OGTT;
1 g/kg BW gavage with dextrose) was conducted afterPublished by Bioscientifica Ltd.
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approved by the UC Davis Institutional Animal Care and
Use Committee. Standard methods for plasma and tissue
analyses are described in detail in the Supplemental
Materials and Methods, see section on supplementary data
given at the end of this article.Statistics and data analysis
Data are presented as meanGS.E.M. Statistical analyses were
performed using GraphPad Prism 4.00 for Windows,
GraphPad Software (San Diego, CA, USA). All time course
datawerecomparedbytwo-factor repeatedmeasuresANOVA
followed by post hoc analysis with Bonferroni’s multiple
comparison test. Incidence data were analyzed by log-rank
testing of Kaplan–Meier survival curves. Age of onset, OGTT
incremental area under the curve (AUC), tissue weights, and
tissue measurements were analyzed by Student’s t-test.
Differences were considered significant at P!0.05.Results
Pioglitazone delays type 2 diabetes onset alone and in
combination with alogliptin
Compared with control animals, pioglitazone admini-
stration alone and in combination with alogliptin
delayed type 2 diabetes onset by w5 months (Fig. 1A).0 1 2 3 4 5 6 7 8 9 10 11 12
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Figure 1
Kaplan–Meier analysis of diabetes incidence in control, alogliptin-,
pioglitazone-, and alogliptinCpioglitazone-treated animals up to
12months (nZ16 per group) (A) and 6months (nZ32 per group) (B) of age.
***P!0.0001 compared with control and alogliptin by log-rank test.
http://joe.endocrinology-journals.org  2014 Society for Endocrinology
DOI: 10.1530/JOE-13-0601 Printed in Great BritainIn the long-term study, the average age of diabetes onset
was 6.0G0.6, 5.8G0.5, 11.0G0.6, and 11.1G0.6 months
in control, alogliptin-, pioglitazone-, and alogliptinC
pioglitazone-treated animals respectively (P!0.001). In
the long-term study, all animals in the control and
alogliptin-treated groups developed diabetes whereas
only 43.8% (7/16) of animals in the pioglitazone and
37.5% (6/16) of animals in the alogliptinCpioglitazone-
treated groups developed diabetes. When data from
animals up to 6 months of age in the long- and short-
term studies were combined, the incidence of diabetes up
to 6 months of age was 0% for both the pioglitazone- and
alogliptinCpioglitazone-treated groups, whereas diabetes
incidence was 53.1% (17/32) and 59.4% (19/32) in the
control and alogliptin-treated groups respectively
(Fig. 1B). The delay of diabetes onset in animals treated
with pioglitazone alone and in combination with
alogliptin was reflected in lower fasting and fed circulating
glucose concentrations and lower HbA1c concentrations
at 5 and 6 months of age compared with the control group
(P!0.001; Fig. 1C, D and E).
Pioglitazone alone and in combination with alogliptin
led to a marked delay in diabetes onset despite its
well-known effects to increase food intake, BW, and
adiposity. Pioglitazone alone and in combination with
alogliptin led to a w10% increase in food intake between
2 and 4.5 months of age and increased BW throughout the
first 6 months of study (P!0.01; Fig. 2A, B and C).0 1 2 3 4 5 6
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Bonferroni’s posttest.
Published by Bioscientifica Ltd.
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Figure 2
Food intake (g/animal per day) (A), food intake (kcal/animal per day) (B),
and body weight (C). ***P!0.001 and **P!0.01 by two-factor repeated
measures ANOVA and Bonferroni’s posttest compared with control and
alogliptin, nZ32 per group.
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compared with the control group. Food intake increased
in the control and alogliptin-treated animals starting at
5 months of age because diabetes prevalence in these
groups had increased resulting in diabetic hyperphagia,http://joe.endocrinology-journals.org  2014 Society for Endocrinology
DOI: 10.1530/JOE-13-0601 Printed in Great Britainas previously reported (Cummings et al. 2008).
The epididymal, retroperitoneal, subcutaneous, and total
white adipose tissue (WAT) weights were significantly
elevated in pioglitazone and alogliptinCpioglitazone
groups compared with the control group (P!0.001);
however, mesenteric adipose depot weight did not differ
between groups (Table 1).Pioglitazone alone and in combination with alogliptin
reduces circulating insulin and lipid concentrations
Similar to previous studies demonstrating that pioglita-
zone markedly improves insulin sensitivity (Ferre 2004,
Kim & Ahn 2004), pioglitazone alone and in combination
with alogliptin significantly reduced fasting plasma insulin
concentrations (Fig. 3A). Insulin concentrations began
to fall in control and alogliptin-treated groups at 5 and
6 months of age because a large proportion of these
animals had developed diabetes and were undergoing
pancreatic b-cell decompensation with the progression
of their diabetes, as previously described (Cummings et al.
2008). Furthermore, pioglitazone alone and in com-
bination with alogliptin resulted in a threefold increase
in circulating adiponectin concentrations (Fig. 3B) with
corresponding increases in AMPK phosphorylation
(Thr172) in subcutaneous WAT and brown adipose tissue
(BAT) (Fig. 3C). Interestingly, animals treated with
alogliptin alone exhibited a significant increase in AMPK
phosphorylation in both subcutaneous BAT and WAT
compared with controls; however, this enhancement of
AMPK signaling was significantly lower than that seen in
pioglitazone-treated animals (P!0.01). Pioglitazone treat-
ment resulted in a twofold increase in fasting plasma leptin
concentrations compared with controls, which was likely
due to the expansion of adiposity (Fig. 3D). Interestingly,
pioglitazone and alogliptin in combination significantly
reduced fasting plasma glucagon concentrations after 2
and 3 months of treatment compared with controls and
compared with pioglitazone and alogliptin alone (Fig. 3E).
Pioglitazone treatment alone and in combination with
alogliptin resulted in improvements of lipid metabolism
including marked reductions of fasting plasma free fatty
acid (FFA), cholesterol, and triglyceride (TG) concentrations
(P!0.001; Fig. 4A, B and C). Enzymes involved in the
regulation of fatty acid oxidation and lipogenesis were
measured in subcutaneous WAT and BAT by immuno-
blotting in order to perform an initial investigation of the
molecular basis for the observed improvement of circulating
lipid concentrations with pioglitazone treatment. Phos-
phorylation and inactivation of acetyl-CoA carboxylasePublished by Bioscientifica Ltd.
Table 1 Tissue weights, tissue TG content, and pancreatic insulin and glucagon content. Values are meanGS.E.M. (nZ16)
Control Alogliptin Pioglitazone AlogliptinCPioglitazone
Epididymal fat depot (g) 8.1G0.4 7.0G0.4* 10.9G0.6‡ 12.0G0.7‡
Retroperitoneal fat depot (g) 12.9G0.6 10.9G0.8* 22.8G1.4‡ 23.3G1.2‡
Subcutaneous depot (g) 45.8G2.8 40.1G3.9 85.1G6.5‡ 94.7G5.0‡
Mesenteric depot (g) 7.2G0.5 5.7G0.6 7.8G0.4 8.1G0.4
Total white adipose tissue (g) 74.8G4.0 64.5G5.6 129.4G8.6‡ 141.1G7.2‡
Heart (g) 1.6G0.1 1.5G0.1 1.7G0.1* 1.7G0.1*
Kidney (g) 2.0G0.1 2.0G0.1 1.9G0.1* 1.9G0.1
Liver (g) 21.1G0.5 20.5G0.4 17.8G0.3‡ 18.8G0.4‡
Liver TG (mmol/g tissue) 25.2G3.2 19.6G4.0 21.0G2.0 19.8G1.9
Skeletal muscle TG (mmol/g tissue) 4.2G0.7 3.0G0.5 7.6G0.9† 7.4G0.7†
Pancreas insulin (mmol/g tissue) 3.4G0.9 2.7G0.8 4.9G0.5 5.3G0.5*
Pancreas glucagon (pmol/g tissue) 95G17 62G8* 72G11 60G11*
*P!0.05, †P!0.01, and ‡P!0.001 compared with control by one-factor ANOVA.
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221 :1 137(ACC Ser79) was elevated in pioglitazone-treated animals in
both BAT and WAT compared with controls (P!0.05),
suggesting an enhancement of fatty acid oxidation (Fig. 4D
and E). Inactive phosphorylated ACC (Ser79) was also
significantly elevated in alogliptin-treated animals in BAT
only (P!0.05; Fig. 4D). Similar to a previous report in
humans (Ranganathan et al. 2006), fatty acid synthase (FAS)
protein expression was elevated with pioglitazone treat-
ment in both BAT and WAT, suggesting an enhancement of
lipogenesis in adipose tissue. Liver TG content did not differ
significantly between groups (Table 1); however, when
diabetic animals were excluded from the control group, liver
TG concentrations were significantly elevated in control2 3
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Figure 3
Fasting plasma insulin (A), adiponectin (B), leptin (D), and glucagon
(E) concentrations. CCCP!0.001 by two-factor repeated measures
ANOVA, ***P!0.001 compared with control and alogliptin, ##P!0.01, and
#P!0.05 for alogliptinCpioglitazone compared with control, alogliptin,
and pioglitazone by Bonferroni’s posttest, nZ32 per group. Representative
http://joe.endocrinology-journals.org  2014 Society for Endocrinology
DOI: 10.1530/JOE-13-0601 Printed in Great Britainanimals (controlZ29.7G3.8 mmol TG/g tissue) compared
with pioglitazone and alogliptinCpioglitazone (P!0.05). By
contrast, skeletal muscle TG concentrations were signi-
ficantly elevated in pioglitazone- and alogliptinCpioglita-
zone-treated animals (Table 1). This difference persisted
when diabetic animals were excluded from the analysis.Pioglitazone and alogliptin improve glucose tolerance
and insulin secretion
Based on the significant improvements of fasting plasma
glucose concentrations with pioglitazone treatment, we
investigated potential improvements of glucose toleranceControl Alo Pio Alo+Pio
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with control by Student’s t-test, nZ16 per group.
Published by Bioscientifica Ltd.
CA
B
Control Alo Pio Alo+Pio
ACC
pACC
FAS
Control Alo Pio Alo+Pio
Tubulin
FAS/Tub
0.0
0.3
0.6
0.9
1.2
1.5
1.8
2.1 ControlAlogliptin
Pioglitazone
*
Alogliptin+pioglitazone
*
*
*
*
Fo
ld
 c
ha
ng
e 
(A
U)
FAS/Tub pACC/ACC
0.0
0.3
0.6
0.9
1.2
1.5
1.8
2.1
Control
Alogliptin
Pioglitazone
*
Alogliptin+pioglitazone
*
*
*
Fo
ld
 c
ha
ng
e 
(A
U)
ACC
pACC
FAS
Tubulin
ED
2 3 4 5 6
0.55
0.65
0.75
0.85
0.95
1.05
1.15
1.25
1.35 +++
*** *********
Control
Alogliptin
Pioglitazone
Alogliptin+pioglitazone
Age (months)
Fa
st
in
g 
pl
as
m
a 
FF
A 
(m
mo
l/l)
2 3 4 5 6
2.0
2.2
2.4
2.6
2.8
3.0
3.2 +++
***
***
***
*
Age (months)
Fa
st
in
g 
pl
as
m
a
ch
ol
es
te
ro
l (m
mo
l/l)
2 3 4 5 6
0.0
0.5
1.0
1.5
2.0 +++
***
***
***
***
Age (months)
Fa
st
in
g 
pl
as
m
a 
TG
(m
mo
l/l)
pACC/ACC
Figure 4
Fasting plasma FFA (A), cholesterol (B), and TG (C) concentrations.
CCCP!0.001 by two-factor repeated measures ANOVA, ***P!0.001, and
*P!0.05 compared with control and aloglitpin by Bonferroni’s posttest,
nZ32 per group. Representative immunoblots for FAS, pACC (Ser79), ACC
and tubulin. All blots were scanned and quantified using FluorChem 9900.
Results were quantified in densitromic units and expressed relative to the
protein of interest or to tubulin for FAS in subcutaneous BAT (D) and WAT
(E). *P!0.05 compared with control by Student’s t-test, nZ16 per group.
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221 :1 138and glucose-stimulated insulin secretion by OGTT (at
5.5 months of age). Glucose excursions during the OGTT
were significantly reduced in all treatment groups compared
with controls. However, the glucose AUC was significantly
lower in animals treated with pioglitazone and alogliptin in
combination compared with either pioglitazone or aloglip-
tin alone, suggesting that pioglitazone and alogliptin act in
an additive manner to improve glucose tolerance (Fig. 5A;
glucose AUC: controlZ549G30, alogliptinZ468G34, pio-
glitazoneZ458G28, and alogliptinCpioglitazoneZ376G
24 mmol/l!120 min; P!0.05).
While fasting plasma insulin concentrations at base-
line were significantly lower in animals treated with
pioglitazone alone and in combination with alogliptin,
the insulin AUC was significantly higher in animals
treated with pioglitazone alone and in combination with
alogliptin compared with control animals (insulin AUC:
controlZ22 039G3506, alogliptinZ19 268G3075, piogli-
tazoneZ33 946G2484, and alogliptinCpioglitazoneZ
34 857G2510 pmol/l!120 min; P!0.05). However, insu-
lin concentrations were significantly lower in pioglita-
zone- and pioglitazoneCalogliptin-treated animals at
multiple time points and all three treatment groups
demonstrated a significantly greater percent increase in
circulating insulin concentrations from baseline to peakhttp://joe.endocrinology-journals.org  2014 Society for Endocrinology
DOI: 10.1530/JOE-13-0601 Printed in Great Britainvalues (% change from baseline: controlZ118G14%,
alogliptinZ206G35%, pioglitazoneZ319G49%, and
alogliptinCpioglitazoneZ458G91%; P!0.05; Fig. 5B).
GLP1 concentrations were measured during the OGTT
in order to identify potential influences of chronic
alogliptin and pioglitazone treatment on endogenous
postprandial GLP1 secretion. Surprisingly, the GLP1 AUC
was significantly lower in animals treated with alogliptin
alone and in combination with pioglitazone (GLP1 AUC:
controlZ130G13, alogliptinZ93G10, pioglitazoneZ
131G13, and alogliptinCpioglitazoneZ101G11 pmol/l!
120 min; P!0.05; Fig. 5C). In order to ensure that
alogliptin treatment was prolonging the half-life of
endogenously secreted active GLP1, the acute effects of
alogliptin administration on plasma active GLP1 concen-
trations was measured in a separate group of male
UCD-T2DM rats. Rats were fasted overnight and the next
morning they received a gavage of dextrose (1 g/kg
dextrose) with or without alogliptin (1 mg/kg BW) and
active GLP1 was measured. Animals receiving alogliptin
exhibited a twofold higher active GLP1 AUC than control
animals, demonstrating that UCD-T2DM rats exhibit
appropriate postprandial increases in active GLP1 (active
GLP1 AUC: controlZ148G19 pmol/l!60 min and
alogliptinZ317G90 pmol/l!60 min; P!0.05; Fig. 5D).Published by Bioscientifica Ltd.
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Figure 5
Circulating glucose (A), insulin (B), and total GLP1 (C) concentrations
during an OGTT at 3.5 months after the initiation of treatment. Animals
were fasted overnight and received a 1 g/kg gavage of a 50% dextrose
solution. CCCP!0.001 for all groups compared with control, and CP!0.05
for alogliptin and alogliptinCpioglitazone compared with control by one-
factor ANOVA of the AUC. ***P!0.05 by one-factor ANOVA of the percent
increase in insulin from baseline to peak values compared with the control
group, nZ32 per group. Plasma active GLP1 in a separate group of male
UCD-T2DM rats (nZ4). Rats were fasted overnight and then received a
gavage of dextrose (1 g/kg) with or without alogliptin mixed in with the
dextrose to provide a dose of 1 mg alogliptin/kg body weight. CP!0.05
compared with control by Student’s t-test of the AUC (D). Representative
immunoblots for pAkt (Ser473), Akt, pERK (Thr202/Tyr204), and ERK in white
adipose tissue. All blots were scanned and quantified using FluorChem
9900. Results were quantified in densitromic units and expressed relative to
the protein of interest (E). *P!0.05 compared with control by Student’s t-
test, nZ16 per group.
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221 :1 139In order to investigate the molecular basis for enhanced
insulin sensitivity in pioglitazone-treated animals, we
analyzed downstream components of insulin signaling
pathways in subcutaneous WAT of fasted animals at study
termination (6.5 months of age). Akt (Ser473) and ERK1/2
(Thr202/Tyr204) phosphorylation, normalized to their
protein expression, were two- to threefold higher in WAT
in animals treated with pioglitazone compared with
controls (P!0.05; Fig. 5E). Alogliptin did not significantly
affect Akt or ERK1/2 phosphorylation.Pioglitazone and alogliptin treatment preserve islet
morphology
In order to investigate the potential effects of pioglitazone
and alogliptin on b-cell mass and islet morphology,
immunostaining for pancreatic insulin and glucagon was
performed in a subset of animals killed at 6.5 months of age.
Cohorts in which none of the animals had developed
diabetes were specifically selected for immunohisto-
chemistry in order to avoid confounding by the presencehttp://joe.endocrinology-journals.org  2014 Society for Endocrinology
DOI: 10.1530/JOE-13-0601 Printed in Great Britainof diabetes. In general, islets from all the three treatment
groups appeared smaller with better preservation of islet
architecture than islets from control animals (Fig. 6A, B, C
and D). Quantification of b-cell mass, average islet size, and
average number of islets per section revealed that control
animals exhibited greater b-cell mass with larger islets and
fewer islets per section compared with all the three
treatment groups (P!0.05; Fig. 6E, F and G).
As a confirmation of the immunohistochemistry data
set, insulin and glucagon were extracted from whole
pancreas samples as an index of b-cell and a-cell mass.
When all animals were included in the analysis, pancreatic
insulin content was significantly higher in pioglitazone-
and pioglitazoneCalogliptin-treated groups compared with
the control and alogliptin treatment groups (Table 1).
However, consistent with the islet immunohistochemistry
results, when diabetic animals were excluded from the
analysis, pancreatic insulin content was significantly higher
in the control animals compared with pioglitazone- and
pioglitazoneCalogliptin-treated groups (excluding diabetic
animals: controlZ7.3G0.9 mmol/g pancreas; P!0.05).Published by Bioscientifica Ltd.
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Representative images from pancreas sections from prediabetic control,
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221 :1 140Interestingly, pancreatic glucagon content was significantly
lower in animals treated with alogliptin alone and in
combination with pioglitazone compared with controls
(P!0.05).Pioglitazone increases markers of mitochondrial
biogenesis
In order to determine whether changes in adipose tissue
mitochondrial biogenesis may be contributing to the
improvements of glucose tolerance with pioglitazone and
alogliptin treatment, markers of energy uncoupling and
mitochondrial biogenesis were measured in subcutaneous
WAT and BAT by RT-PCR. All the three treatment groups
exhibited significant increases in uncoupling protein 1
(UCP1), peroxisome proliferator-activated receptor g
coactivator 1a (PGC1a), and cytochrome c oxidase subunit
8b (Cox8b) mRNA in BAT and WAT (Fig. 7A and B). UCP1 is
an inner mitochondrial membrane transporter of FFAs that
allows for the dissipation of energy as heat (Cardoso et al.
2010). PGC1a is a key transcriptional regulator of oxidative
metabolism and Cox8b is a gene involved in mitochondrial
oxidative phosphorylation that is upregulated by PGC1a.
Increases in markers of mitochondrial biogenesis were more
pronounced in pioglitazone-treated animals than inhttp://joe.endocrinology-journals.org  2014 Society for Endocrinology
DOI: 10.1530/JOE-13-0601 Printed in Great Britainanimals receiving alogliptin alone (P!0.05). Addition
of alogliptin to pioglitazone treatment did not produce
an additional elevation in UCP1 or PGC1a expression.
However, alogliptin and pioglitazone in combination
resulted in higherCox8bmRNA levels than either alogliptin
or pioglitazone alone (P!0.05).Discussion
Results from previous studies have suggested that piogli-
tazone and alogliptin in combination may act synergisti-
cally to provide greater glucose-lowering effects than
either agent alone (DeFronzo et al. 2008, Pratley et al.
2009a, Rosenstock et al. 2009, Kaku et al. 2011, Eliasson
et al. 2012). However, the efficacy of alogliptin alone and
in combination with pioglitazone to delay the onset of
type 2 diabetes has not been previously assessed. In this
study, we report that while pioglitazone and alogliptin
both produced metabolic benefits, the addition of
alogliptin at a dose of 20 mg/kg per day to pioglitazone
treatment did not produce a greater delay in diabetes onset
than pioglitazone alone. Furthermore, alogliptin did not
produce a delay in diabetes onset at this dose on its own.
Of note, only one dose of alogliptin was tested in this
study. While this dose is similar to or higher than doses ofPublished by Bioscientifica Ltd.
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221 :1 141alogliptin employed in most previously published rodent
studies (Feng et al. 2007, Lee et al. 2008, Asakawa et al.
2009), there is a possibility that the efficacy of alogliptin
would have been enhanced at a higher dose. By contrast,
pioglitazone alone and in combination with alogliptin
delayed type 2 diabetes onset by w5 months compared
with control UCD-T2DM rats.
The effect of pioglitazone to delay diabetes onset was
independent of food intake and BW as both were higher in
pioglitazone-treated animals compared with controls.
Numerous studies on rodents and humans have reported
that TZDs increase BW by increasing adipogenesis, fluid
retention, and food intake (Shimizu et al. 1998, Lehrke
et al. 2005). Similar to previous studies, alogliptin did not
affect food intake or BW (Kawashima et al. 2011, Shah et al.
2011). Increases of adiposity in pioglitazone-treated
animals primarily involved the subcutaneous adipose
depot and not the mesenteric adipose depot. Previous
studies have shown that the effect of TZDs to increase
adiposity is primarily restricted to the subcutaneous
adipose depot, sparing the more metabolically detrimentalhttp://joe.endocrinology-journals.org  2014 Society for Endocrinology
DOI: 10.1530/JOE-13-0601 Printed in Great Britainvisceral depot, allowing for improved insulin sensitivity
in the face of increased adiposity (Miyazaki et al. 2002).
Pioglitazone and alogliptin appear to act in an additive
manner to improve glucose tolerance and insulin secretion
during the OGTT. Furthermore, fasting plasma insulin
concentrations were lower and activation of downstream
insulin signaling proteins were higher in pioglitazone-
treated animals, suggesting that improvements of insulin
sensitivity likely contributed to the improvement of
glucose tolerance with pioglitazone treatment. The effect
of pioglitazone treatment to improve insulin sensitivity
has been previously described in both human clinical
studies and studies on rodents (Olefsky 2000, Ferre 2004).
We hypothesize that the decrease in GLP1 secretion during
the OGTT in alogliptin-treated animals is likely due to
downregulation of GLP1 secretion over time following
repeated increases in postprandial GLP1 secretion.
Islet immunohistochemistry revealed marked
improvements of islet morphology in all treatment groups
compared with the control group. We hypothesize that
b-cell mass was lower in the groups treated with
pioglitazone because these groups were more insulin
sensitive resulting in less islet hypertrophy. The improve-
ment of islet morphology in alogliptin-treated animals
was surprising in light of alogliptin’s lack of effect on
diabetes onset. This suggests that the development of
type 2 diabetes in the UCD-T2DM rat is, at least initially,
more heavily reliant on development of insulin resistance.
The effect of alogliptin to reduce pancreatic glucagon
content is in line with previous studies reporting that
GLP1 signaling results in decreased glucagon secretion
from a-cells, partially indirectly due to GLP1-induced
pancreatic somatostatin secretion (Fehmann & Habener
1991). The effect of alogliptin to reduce pancreatic
glucagon likely contributed to the effect of alogliptin in
combination with pioglitazone to reduce circulating
glucagon concentrations and represents a metabolic
benefit of addition of alogliptin to pioglitazone therapy.
Another potential mechanism by which pioglitazone
treatment delayed diabetes onset is by increasing circulating
adiponectin concentrations leading to subsequent increases
in AMPK activation. Activation of AMPK promotes glucose
uptake and lipid oxidation and inhibits glucose and lipid
production (Long & Zierath 2006). We confirmed that
pioglitazone treatment increases AMPK activation with
corresponding increases in phosphorylation and inacti-
vation of ACC in BAT and subcutaneous WAT. Previous
studies have demonstrated that AMPK can inactive ACC
resulting in reduced malonyl-CoA concentrations, which
enhances the movement of long-chain acyl-CoA into thePublished by Bioscientifica Ltd.
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221 :1 142mitochondria for b-oxidation (Winder & Hardie 1996,
Winder et al. 1997). These findings suggest that pioglitazone
treatment promotes an increase in fatty acid oxidation in
adipose tissue, which likely contributed to the decreases
in circulating and liver lipid concentrations; however,
further studies are needed to confirm these findings. This
reduction of hepatic lipid deposition likely contributed to
the improvement of insulin sensitivity with pioglitazone
treatment as lipid deposition in liver has been shown to
inhibit insulin signaling through promotion of serine
phosphorylation of insulin receptor substrate proteins
(Samuel & Shulman 2012). Surprisingly, TG deposition
was increased in skeletal muscle in pioglitazone-treated
animals compared with controls despite improvements of
fasting plasma insulin concentrations and glucose tole-
rance observed with pioglitazone treatment. Interestingly,
a previous study on human type 2 diabetic patients reports
that treatment with pioglitazone improves insulin sensi-
tivity without altering skeletal muscle TG deposition (Rabol
et al. 2010). Furthermore, a previous study in sucrose-fed
rats reports an increase in muscle TG deposition with
pioglitazone treatment (Markova et al. 2010). By contrast,
pioglitazone treatment also appears to enhance fatty acid
synthesis as indicated by increased protein expression of
FAS in BAT and WAT. This is similar to a previous report
on humans and suggests that pioglitazone also reduces
hepatic ectopic lipid deposition by diverting lipid into
adipose stores (Ranganathan et al. 2006). In line with this
finding, studies have shown that increases in de novo
lipogenesis in WAT improve insulin sensitivity (Cao et al.
2008, Roberts et al. 2009, Eissing et al. 2013).
Interestingly, alogliptin treatment also resulted in a
small but significant elevation of AMPK activation in BAT
and subcutaneous WAT and inactivation of ACC in BAT.
However, alogliptin treatment did not produce decreases
in circulating lipid concentrations or ectopic lipid
deposition, similar to what has been reported in previous
clinical studies (Bosi et al. 2011). This suggests that these
modest elevations of AMPK activity are not sufficient to
lower circulating lipids or ectopic lipid deposition.
Increases in markers of mitochondrial biogenesis in
WAT and BAT may have also contributed to the delay
in diabetes onset in pioglitazone-treated animals. BAT is
highly thermogenic leading to the loss of energy as heat
and subsequent BW loss. Recent reports have revealed
that WAT has the capacity to express a BAT-like pheno-
type under certain conditions such as cold exposure,
b-adrenergic stimulation, and PPARg agonism (Kajimura
et al. 2010). Results from previous studies indicate that
PPARg agonists can enhance the thermogenic activity ofhttp://joe.endocrinology-journals.org  2014 Society for Endocrinology
DOI: 10.1530/JOE-13-0601 Printed in Great BritainBAT and can induce a WAT-to-BAT conversion by
activating PPARg and PPAR response elements on the
promoter and/or enhancer region of brown adipose genes
(Sears et al. 1996, Ohno et al. 2012). Increased markers of
mitochondrial biogenesis in BAT and WAT with pioglita-
zone treatment corresponded with increased markers of
b-oxidation. Previous studies have reported that pioglita-
zone does not increase energy expenditure despite its
effects on mitochondrial biogenesis but that it does
increase the capacity for sympathetically mediated energy
expenditure in rodents (Sell et al. 2004). However,
increases in mitochondrial biogenesis may have also
contributed to the improvements of lipid metabolism
with pioglitazone treatment by favoring the use of lipids
for energy through b-oxidation.
Interestingly, alogliptin-treated animals also exhib-
ited increases in markers of mitochondrial biogenesis
compared with control animals, although these increases
were less dramatic than those observed in pioglitazone-
treated animals. These results are similar to those from a
previous report that another DDP-IV inhibitor, des-fluoro-
sitagliptin, increases mRNA expression of UCP1 and
PGC1a in BAT (Shimasaki et al. 2013).
In conclusion, we have demonstrated that pioglitazone
markedly delays the onset of type 2 diabetes in the UCD-
T2DM rat and that this delay in onset is not enhanced by
co-administration with alogliptin. Alogliptin treatment at a
dose of 20 mg/kg per day resulted in modest improvements
of glucose tolerance, glucose-stimulated insulin secretion,
islet morphology, and markers of mitochondrial bio-
genesis. While alogliptin is effective in the management
of type 2 diabetic patients (Bosi et al. 2011, DeFronzo et al.
2012), the metabolic improvements observed with alog-
liptin treatment in prediabetic UCD-T2DM rats do not
appear to be sufficiently robust to result in a delay in
diabetes onset alone or in combination with pioglitazone.Supplementary data
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Supplementary Material 
 
Materials and Methods: 
Monthly Hormone and Metabolic Profiles  
Blood samples were collected from rats in both the short term and long term treatment 
groups once a month after an overnight (13 hour) fast and placed into EDTA treated tubes. The 
plasma was separated by centrifugation and assayed for glucose, insulin, glucagon, free fatty 
acids (FFA), triglycerides (TG), cholesterol, leptin and adiponectin.  Whole blood samples were 
collected for the measurement of HbA1c. Plasma glucose, cholesterol, FFA and TG 
concentrations were measured using enzymatic colorimetric assays (Thermo DMA Louisville, 
CO).  Leptin, glucagon and adiponectin were measured with rodent/rat specific RIAs (Millipore, 
St. Charles, MO).  HbA1c was measured using an enzymatic colorimetric assay (Diazyme; 
Poway, CA). 
 
Oral Glucose Tolerance Testing 
An OGTT was performed after 3.5 months of treatment on animals from the short term 
and long term groups. Animals were fasted overnight and then received a 50% dextrose solution 
(1 g/kg BW) by oral gavage. Blood was collected from the tail for measurement of glucose and 
insulin concentrations. A second aliquot of blood was placed in tubes containing EDTA, 
aprotinin and a DPP-IV inhibitor and analyzed for total GLP-1. Serum glucose was measured 
using an enzymatic colorimetric assay for glucose (Thermo DMA Louisville, CO). Serum 
insulin and plasma GLP-1 were measured by sandwich electrochemiluminescence immunoassay 
(Meso Scale Discovery; Gaithersburg, MA).  
The same procedure was followed for the performance of an acute study of the effects of 
alogliptin administration on circulating concentrations of active GLP-1. A separate set of male 
UCD-T2DM rats were fasted overnight and received an oral gavage of dextrose (1 g/kg) with or 
without alogliptin added to the gavage (1 mg alogliptin/kg body weight).  
 
Body Composition and Liver and Muscle Triglyceride Content  
 After 4.5 months of treatment (6.5 months of age) animals in the short-term groups were 
euthanized with an overdose of pentobarbital (200 mg/kg i.p.) after an overnight fast. 
Subcutaneous, mesenteric, retroperitoneal and epididymal adipose depots and liver, heart, 
gastrocnemius muscle and kidney were dissected, weighed and flash frozen in liquid nitrogen 
and stored at -80 °C. Liver and skeletal muscle TG content were measured using the Folch 
method [33] for lipid extraction followed by spectrophotmetric measurement of TG content 
(Thermo Electron, Louisville, CO).  
 
Islet Immunohistochemistry and Pancreatic Insulin Content 
 Pancreas samples were collected and insulin and glucagon were extracted and analyzed 
as previously described [34]. Pancreas samples were also collected from a subset of animals for 
immunohistochemistry, as previously described [35]. Briefly, samples were fixed in 4% 
paraformaldehyde and embedded in paraffin. Ten sections (1µm) per pancreas were obtained. 
Sections were deparafinized in a xylene ethanol series and placed in Tris-EDTA buffer for 
antigen retrieval (10mM Tris, 1mM EDTA, 0.05% Tween, pH=9.0) and then blocked in 5% 
BSA. Sections were immunostained for insulin using a monoclonal anti-mouse antibody (1:100) 
and for glucagon using monoclonal anti-rabbit antibody (1:50) (Santa Cruz Biotechnology; 
Dallas, TX). Detection of the primary antibodies was performed using Alexa Flour 488 anti-goat 
and Alexa Flour 633 anti-mouse secondary antibodies (1:200) (Invitrogen; Foster City, CA). 
Nuclei were detected using 4′,6′-diamino-2-phenyl inodole (DAPI), included in the mounting 
solution (Invitrogen; Foster City, CA). Ten sections per pancreas, taken throughout the pancreas, 
were imaged for quantification. Pancreatic β-cell area was analyzed using Image J software.  
 
rtPCR 
RNA was extracted from brown and subcutaneous white adipose tissue using TRIzol 
reagent (Invitrogen, CA). cDNA was generated using high-capacity cDNA Archive Kit 
(SuperScript™ III Reverse Transcriptase, Invitrogen). mRNA of UCP1, Cox8b and PGC1α was 
assessed by reverse transcription PCR (iCycler, BioRad) and normalized to β-actin. For RT-
PCR, Absolute blue qPCR premix (Fisher Scientific) was mixed with each primer. UCP1 
primers: 5′- ATACTGGCAGATGACGTCCC -3′ (For.), 5′-ATCCGAGTCGCAGAAAAGAA-
3′(Rev.); Cox8b primers: 5′- CCGAGAATCATGCCAAGGCT -3′ (For.), 5′- 
TCCTGCTGGAACCATGAAGC -3′ (Rev.); PGC1α primers: 5′- 
TAGCGGTCCTCACAGAGACA-3′ (For.),  5′- AGTGCTAAGACCGCTGCATT-3′ (Rev.); β-
actin primers: 5′- CACGGCATTGTCACCAACTG-3′ (For.), 5′- 
GGGGTGTTGAAGGTCTCAAA-3′ (Rev.).  
 
Immunoblotting 
Tissues were ground in the presence of liquid nitrogen and lysed using radio-
immunoprecipitation assay (RIPA) buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% 
sodium dodecyl sulfate [SDS], 1% Triton X-100, 1% sodium deoxycholate, 5 mM EDTA, 1 mM 
NaF, 1 mM sodium orthovanadate and protease inhibitors). Lysates were clarified by 
centrifugation at 13,000 rpm for 10 min and protein concentrations were determined using 
bicinchoninic acid protein assay kit (Pierce Chemical, IL). Proteins (20-50ug) were resolved by 
SDS-PAGE (10-12%) and transferred to PVDF membranes. Immunoblots were performed with 
the relevant antibodies and proteins were visualized using Luminata™ Forte (Millipore; 
Billerica, MA). For quantitation purposes, pixel intensities of immuno-reactive bands from blots 
that were in the linear range of loading and exposure were quantified using FluorChem 9900 
(Alpha Innotech, CA). Antibodies for FAS, PGC1α and Tubulin were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Antibodies for acetyl-CoA carboxylase (ACC), pACC 
(Ser79), AMP-activated protein kinase (AMPK), pAMPK (Thr172), protein kinase B (AKT), 
pAKT (Ser473), extracellular-signal-regulated kinase1/2 (ERK1/2) and pERK1/2 (Thr202/Tyr204) 
were from Cell Signaling (Beverly, MA). Horseradish peroxidase (HRP)-conjugated secondary 
antibodies were purchased from BioResources International (Carlsbad, CA).  
 
 
 
